Second season results from the Phase 3 SMART trial were presented at the 9 th RSVVW Conference and will be shared with the U.S. FDA and other regulatory authorities
Strategic collaboration brings together Mayo Clinic's extensive clinical insights, genomic data and Platform architecture with Merck's artificial intelligence (AI) and machine learning (ML) research capabilities...
Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival...
KEYTRUDA and KEYTRUDA QLEX are the first and only PD-1 inhibitors approved for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma with PD-L1+ tumors ...
5 Revealing Analyst Questions From Merck’s Q4 Earnings Call
/Moderna%20Inc%20meds-by%20Ascannio%20via%20Shutterstock.jpg)
Moderna is betting its mRNA pipeline can power the next growth cycle.
MRK Q4 Deep Dive: Pipeline Expansion and New Product Launches Shape Guidance
The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.84%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.34%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.55%. March E-mini...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.35%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.94%. March E-mini S&P futures (ESH26...